Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Nuclear Medicine Communications|August 1, 1996
Complications and difficulties in radiolabelling blood cells: a reviewC B Sampson
Nuclear Medicine Communications|May 11, 1999
Interference of patient medication in the radiolabelling of white blood cells: an updateC B Sampson
Drug Safety|April 1, 1993
Adverse reactions and drug interactions with radiopharmaceuticalsC B Sampson
Nuclear Medicine Communications|March 1, 1991
Purification of radioiodinated monoclonal antibodies using a simple 'closed procedure' deviceC B Sampson, C Solanki
Nuclear Medicine Communications|October 1, 1991
Technetium-labelled autologous lymphocytes: clinical protocol for radiolabelling using a high concentration and low volume of 99Tcm-exametazimeC B Sampson, E Goffin
Nuclear Medicine Communications|June 1, 1985
Stability of 99Tcm-DTPA injection: effect of delay after preparation, dilution, generator oxidant, air and oxygenC B Sampson, J Keegan
Nuclear Medicine Communications|February 1, 1988
Technetium-labelled leucocytes using diethyldithiocarbamate: preliminary report on in vitro studiesC B Sampson, C Solanki
The British Journal of Radiology|December 1, 1984
Adverse reactions to radiopharmaceuticals. United Kingdom 1977-1983D H Keeling, C B Sampson
Nuclear Medicine Communications|August 1, 1991
99Tcm-exametazime-labelled leucocytes: effect of volume and concentration of exametazime on labelling efficiency, and clinical protocol for high efficiency multi-dose radiolabellingC B Sampson, C Solanki, R W Barber
Nuclear Medicine Communications|May 11, 1999
Seven-hour stabilization of 99Tcm-exametazime (HMPAO) for cerebral perfusionC Solanki, E P Wraight, R W Barber, et al.
Pageof 2